3.82
-0.345(-8.29%)
Currency In USD
Address
230 Park Avenue
New York, NY 10169
United States of America
Phone
646 885 8505
Website
Sector
Healthcare
Industry
Biotechnology
Employees
104
First IPO Date
September 21, 2018
| Name | Title | Pay | Year Born |
| Mr. Michael Rossi | Chief Executive Officer, President & Director | 1.1M | 1971 |
| Mr. Peter P. Pfreundschuh CPA | Executive Vice President, Chief Financial Officer & Treasurer | 594,252 | 1969 |
| Mr. Thomas Gad | Founder, Chief Business Officer & Vice Chairman | 911,886 | 1970 |
| Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior Vice President & Chief Technology Officer | 0 | 1951 |
| Ms. Courtney Dugan | Vice President of Investor Relations | 0 | N/A |
| Mr. John W. LaRocca Esq. | Senior Vice President, General Counsel, Secretary & Chief Legal Officer | 0 | 1965 |
| Mr. Doug Gentilcore | Senior Vice President & Head of DANYELZA Business Unit | 0 | 1980 |
| Ms. Natalie Tucker | Senior Vice President & Radiopharmaceutical Business Unit Head | 0 | N/A |
| Mr. Joris Wiel Jan Wilms | Senior Vice President & Chief Operating Officer | 0 | 1974 |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer | 0 | 1948 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.